(NNOX) Nano X Imaging - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 128m USD | Total Return: -61.8% in 12m
Avg Turnover: 2.12M
Qual. Beats: -1
Rev. Trend: 96.3%
Qual. Beats: -1
Warnings
Interest Coverage Ratio -426.3 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Nano-X Imaging Ltd. (NNOX) is a medical technology company specializing in the development of a digital X-ray source and a commercial-grade tomographic imaging system. The company’s core hardware, the Nanox.ARC, is designed to integrate with Nanox.CLOUD, a proprietary platform that utilizes matching engines to connect medical images with radiologists and AI-driven diagnostic tools. This ecosystem aims to streamline the imaging workflow through integrated billing, reporting, and image repository services.
The company operates within the medical imaging sector, which is increasingly shifting toward digital hardware to reduce the footprint and cost associated with traditional analog X-ray tubes. Nano-X’s business model extends beyond hardware sales into teleradiology and AI-based software services, targeting hospitals and insurers by providing automated data mining of CT scans to identify underdiagnosed medical conditions. This multi-layered approach combines capital equipment placement with recurring service revenue from marketplace and interpretation fees.
Investors should consult ValueRay for further data on the companys market positioning and valuation metrics. Headquartered in Israel, Nano-X continues to focus on obtaining regulatory approvals and expanding its marketplace to connect global imaging facilities with remote diagnostic expertise.
- FDA clearance and commercial deployment of Nanox.ARC imaging systems
- Growth in recurring revenue from teleradiology and AI diagnostics
- Manufacturing scale-up efficiency impacts gross margins and cash burn
- Global regulatory approvals determine expansion into emerging medical markets
- Adoption rates of pay-per-scan business model versus traditional sales
| Net Income: -95.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA -9.73 > 1.0 |
| NWC/Revenue: 358.4% < 20% (prev 477.6%; Δ -119.2% < -1%) |
| CFO/TA -0.27 > 3% & CFO -44.3m > Net Income -95.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.1m) vs 12m ago 4.87% < -2% |
| Gross Margin: -98.04% > 18% (prev -1.01%; Δ -9.70k% > 0.5%) |
| Asset Turnover: 7.76% > 50% (prev 5.87%; Δ 1.89% > 0%) |
| Interest Coverage Ratio: -426.3 > 6 (EBITDA TTM -51.9m / Interest Expense TTM 149k) |
| A: 0.31 (Total Current Assets 66.8m - Total Current Liabilities 16.9m) / Total Assets 162.2m |
| B: -2.77 (Retained Earnings -448.8m / Total Assets 162.2m) |
| C: -0.35 (EBIT TTM -63.5m / Avg Total Assets 179.5m) |
| D: -20.00 (Book Value of Equity -448.6m / Total Liabilities 22.4m) |
| Altman-Z'' = -30.38 = D |
| DSRI: 0.97 (Receivables 2.01m/1.72m, Revenue 13.9m/11.5m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.95 (AQ_t 0.38 / AQ_t-1 0.40) |
| SGI: 1.21 (Revenue 13.9m / 11.5m) |
| TATA: -0.31 (NI -95.2m - CFO -44.3m) / TA 162.2m) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 1.98 with a total of 2,741,122 shares traded.
Over the past week, the price has changed by +16.47%,
over one month by +6.45%,
over three months by -20.16% and
over the past year by -61.78%.
Nano X Imaging has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy NNOX.
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7.2 | 263.6% |
P/S = 9.8338
P/B = 0.9164
Revenue TTM = 13.9m USD
EBIT TTM = -63.5m USD
EBITDA TTM = -51.9m USD
Long Term Debt = 3.77m USD (estimated: total debt 7.85m - short term 4.09m)
Short Term Debt = 4.09m USD (from shortTermDebt, last quarter)
Debt = 12.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.71m
Net Debt = -47.0m USD (calculated: Debt 12.6m - CCE 59.6m)
Enterprise Value = 81.0m USD (128.0m + Debt 12.6m - CCE 59.6m)
Interest Coverage Ratio = -426.3 (Ebit TTM -63.5m / Interest Expense TTM 149k)
EV/FCF = -1.64x (Enterprise Value 81.0m / FCF TTM -49.3m)
FCF Yield = -60.82% (FCF TTM -49.3m / Enterprise Value 81.0m)
FCF Margin = -353.8% (FCF TTM -49.3m / Revenue TTM 13.9m)
Net Margin = -683.3% (Net Income TTM -95.2m / Revenue TTM 13.9m)
Gross Margin = -98.04% ((Revenue TTM 13.9m - Cost of Revenue TTM 27.6m) / Revenue TTM)
Gross Margin QoQ = -97.26% (prev -105.2%)
Tobins Q-Ratio = 0.50 (Enterprise Value 81.0m / Total Assets 162.2m)
Interest Expense / Debt = 1.19% (Interest Expense 149k / Debt 12.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -50.2m (EBIT -63.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.96 (Total Current Assets 66.8m / Total Current Liabilities 16.9m)
Debt / Equity = 0.09 (Debt 12.6m / totalStockholderEquity, last quarter 139.7m)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -47.0m / EBITDA -51.9m)
Debt / FCF = 0.95 (negative FCF - burning cash) (Net Debt -47.0m / FCF TTM -49.3m)
Total Stockholder Equity = 149.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.02% (Net Income -95.2m / Total Assets 162.2m)
RoE = -15.89% (Net Income TTM -95.2m / Total Stockholder Equity 598.7m)
RoCE = -10.54% (EBIT -63.5m / Capital Employed (Equity 598.7m + L.T.Debt 3.77m))
RoIC = -48.93% (negative operating profit) (NOPAT -50.2m / Invested Capital 102.6m)
WACC = 12.77% (E(128.0m)/V(140.6m) * Re(13.93%) + D(12.6m)/V(140.6m) * Rd(1.19%) * (1-Tc(0.21)))
Discount Rate = 13.93% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 94.39 | Cagr: 6.86%
[DCF] Fair Price = unknown (Cash Flow -49.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 96.29 | Revenue CAGR: 13.38% | SUE: -1.31 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.14 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=-0.48 | Chg30d=-336.36% | Revisions=+20% | GrowthEPS=+25.0% | GrowthRev=+136.2%
EPS next Year (2027-12-31): EPS=-0.20 | Chg30d=-300.00% | Revisions=-20% | GrowthEPS=+58.3% | GrowthRev=+90.3%